Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option

  • Scheme Category:  
  • Equity Scheme >  
NAV: ₹ 612.0531 ↑ 0.07%
[as on 12 October, 2026]

NAV chart

SMA (Simple Moving Average)

  • 50 SMA
  • 100 SMA
  • 200 SMA
  • 400 SMA

Returns

CAGR returns till date

CAGR returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option and its peers as on 12 October, 2026
NameYTD1D1W1M3M1Y3Y5Y7Y10Y
Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option 7.47% 0.07% -1.49% -4.12% -3.12% 6.99% 16.91% 12.93% 22.62% 15.12%
Nippon India Banking & Financial Services Fund - Direct Plan Growth Plan - Growth Option -6.96% 0.13% 0.65% -4.22% -7.07% -2.44% 10.22% 11.5% 14.27% 12.59%
Nippon India Power & Infra Fund - Direct Plan Growth Plan - Growth Option 4.93% 0.38% -0.92% -3.88% -4.59% 4.59% 16.2% 18.79% 22.51% 17.27%
DSP Healthcare Fund - Direct Plan - Growth 13.3% -0.17% -0.76% -2.75% -0.51% 13.72% 20.31% 15.19% 25.77%-
DSP Banking & Financial Services Fund - Direct - Growth -0.75% -0.16% 0.34% -5.74% -5.85% 5.47%----
BANDHAN Infrastructure Fund-Direct Plan-Growth -3.14% -0.08% -1.93% -4.05% -7.93% -5.95% 13.34% 15.49% 20.56% 15.29%

Discrete returns (yearly)

Year2016201720182019202020212022202320242025
Returns -9.42% 8.09% 4.71% 2.97% 68.53% 23.84% -9.16% 41.33% 35.46% -2.94%

Discrete returns (monthly)

MonthDec 2025Jan 2026Feb 2026Mar 2026Apr 2026May 2026Jun 2026Jul 2026Aug 2026Sep 2026
Returns -1.24% -4.66% 5.31% -4.85% 6.03% 2.37% 5.46% 2.71% 2.06% -2.68%

Returns from spefic dates

DescriptionCAGR returns from 18 Oct 2021 (Nifty 50 2021 high)CAGR returns from 26 Sep 2024 (Nifty 50 2024 high)
Returns 12.92% 3.01%

Portfolio

Asset allocation

EquityDebtRealestateCommoditiesCash & Equivalents
97.99% 0.00% (Arbitrage: 0.00%) 0.00% 0.00% 2.01%

Equity

NameSymbol / ISINSectorWeight %Other links
Sun Pharmaceutical Industries LimitedSUNPHARMA (INE044A01036)Pharmaceuticals & Biotechnology12.37%
Divi's Laboratories LimitedDIVISLAB (INE361B01024)Pharmaceuticals & Biotechnology7.00%
Lupin LimitedLUPIN (INE326A01037)Pharmaceuticals & Biotechnology6.43%
Cipla LimitedCIPLA (INE059A01026)Pharmaceuticals & Biotechnology6.09%
Apollo Hospitals Enterprise LimitedAPOLLOHOSP (INE437A01024)Healthcare Services5.15%
Dr. Reddy's Laboratories LimitedDRREDDY (INE089A01031)Pharmaceuticals & Biotechnology4.93%
Mankind Pharma LimitedMANKIND (INE634S01028)Pharmaceuticals & Biotechnology4.09%
Sai Life Sciences LimitedSAILIFE (INE570L01029)Pharmaceuticals & Biotechnology3.94%
Ajanta Pharma LimitedAJANTPHARM (INE031B01049)Pharmaceuticals & Biotechnology3.47%
GlaxoSmithKline Pharmaceuticals LimitedGLAXO (INE159A01016)Pharmaceuticals & Biotechnology3.31%
Max Healthcare Institute LimitedMAXHEALTH (INE027H01010)Healthcare Services2.92%
IPCA Laboratories LimitedIPCALAB (INE571A01038)Pharmaceuticals & Biotechnology2.84%
Vijaya Diagnostic Centre LimitedVIJAYA (INE043W01024)Healthcare Services2.68%
MedPlus Health Services LimitedMEDPLUS (INE804L01022)Retailing2.51%
Thyrocare Technologies LimitedTHYROCARE (INE594H01019)Healthcare Services2.45%
Gland Pharma LimitedGLAND (INE068V01023)Pharmaceuticals & Biotechnology2.44%
Piramal Pharma LimitedPPLPHARMA (INE0DK501011)Pharmaceuticals & Biotechnology2.25%
Abbott India LimitedABBOTINDIA (INE358A01014)Pharmaceuticals & Biotechnology2.13%
Dr. Lal Path Labs LimitedLALPATHLAB (INE600L01024)Healthcare Services2.04%
Alkem Laboratories LimitedALKEM (INE540L01014)Pharmaceuticals & Biotechnology1.82%
Narayana Hrudayalaya LimitedNH (INE410P01011)Healthcare Services1.66%
Aurobindo Pharma LimitedAUROPHARMA (INE406A01037)Pharmaceuticals & Biotechnology1.63%
Pfizer LimitedPFIZER (INE182A01018)Pharmaceuticals & Biotechnology1.57%
Syngene International LimitedSYNGENE (INE398R01022)Healthcare Services1.48%
Suraksha Diagnostic LimitedSURAKSHA (INE877V01027)Healthcare Services1.39%
Fortis Healthcare LimitedFORTIS (INE061F01013)Healthcare Services1.29%
Emcure Pharmaceuticals LimitedEMCURE (INE168P01015)Pharmaceuticals & Biotechnology1.25%
Anthem Biosciences LimitedANTHEM (INE0CZ201020)Pharmaceuticals & Biotechnology1.20%
Akums Drugs and Pharmaceuticals LimitedAKUMS (INE09XN01023)Pharmaceuticals & Biotechnology1.11%
Biocon LimitedBIOCON (INE376G01013)Pharmaceuticals & Biotechnology1.09%
Sanofi India LimitedSANOFI (INE058A01010)Pharmaceuticals & Biotechnology0.99%
Sanofi Consumer Healthcare India LimitedSANOFICONR (INE0UOS01011)Pharmaceuticals & Biotechnology0.93%
Indoco Remedies LimitedINDOCO (INE873D01024)Pharmaceuticals & Biotechnology0.47%
AstraZeneca Pharma India LimitedASTRAZEN (INE203A01020)Pharmaceuticals & Biotechnology0.46%
Molbio Diagnostics Limited (INE869T01028)Healthcare Equipment & Supplies0.44%
Concord Biotech LimitedCONCORDBIO (INE338H01029)Pharmaceuticals & Biotechnology0.17%
Portfolio data is as on date 31 August, 2026

NAV history

Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option - 30 days NAV (Net asset value) history

DateNAV% change
12 October, 2026612.0531 0.07%
9 October, 2026611.6235 0.35%
8 October, 2026609.4803 -2.55%
7 October, 2026625.4065 -0.37%
6 October, 2026627.7179 1.03%
5 October, 2026621.3187 -1.13%
1 October, 2026628.4076 -0.29%
30 September, 2026630.2169 -1.69%
29 September, 2026641.0190 0.24%
28 September, 2026639.5116 -0.8%
25 September, 2026644.6841 -0.36%
24 September, 2026647.0082 -0.55%
23 September, 2026650.6031 0.62%
22 September, 2026646.5722 -0.43%
21 September, 2026649.3465 0.87%
18 September, 2026643.7329 0.87%
17 September, 2026638.1725 1.21%
16 September, 2026630.5186 -0.26%
15 September, 2026632.1723 -0.97%
11 September, 2026638.3641 -0.22%
10 September, 2026639.7674 -0.56%
9 September, 2026643.4016 -0.34%
8 September, 2026645.5743 0.31%
7 September, 2026643.5936 0.24%
4 September, 2026642.0816 -0.57%
3 September, 2026645.7740 -0.17%
2 September, 2026646.8638 -0.11%
1 September, 2026647.5641 -0.93%
31 August, 2026653.6135 0.61%
28 August, 2026649.6782

FAQ (Frequently asked questions)

  • What is latest/current NAV/price of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
    The latest NAV of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option is 612.0531 as on 12 October, 2026.
  • What are YTD (year to date) returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
    The YTD (year to date) returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 7.47% as on 12 October, 2026.
  • What are 1 year returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
    The 1 year returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 6.99% as on 12 October, 2026.
  • What are 3 year CAGR returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
    The 3 year annualized returns (CAGR) of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 16.91% as on 12 October, 2026.
  • What are 5 year CAGR returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
    The 5 year annualized returns (CAGR) of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 12.93% as on 12 October, 2026.
  • What are 10 year CAGR returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
    The 10 year annualized returns (CAGR) of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 12.93% as on 12 October, 2026.
  • What are top 10 holdings of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
    Top 10 holdings of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are:
    • Sun Pharmaceutical Industries Limited
    • Divi's Laboratories Limited
    • Lupin Limited
    • Cipla Limited
    • Apollo Hospitals Enterprise Limited
    • Dr. Reddy's Laboratories Limited
    • Mankind Pharma Limited
    • Sai Life Sciences Limited
    • Ajanta Pharma Limited
    • GlaxoSmithKline Pharmaceuticals Limited
    • Max Healthcare Institute Limited
  • What is LTCG (Long term capital gain) and STCG (Short term capital gain) tax for Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
    Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option is equity oriented mutual fund. Various capital gain taxes are applicable as below (Effective for redemption after July 23, 2024 and from FY 2024-25)
    Holding periodTax rate
    Less than 1 year (STCG)20%
    More than 1 year (LTCG)Tax free upto Rs. 1.25 lakhs. 12.5% on rest amount.